MARKET REPORT

Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021)

BioPortfolio
Life Science Healthcare and Pharmaceutical Market Research and Corporate Data
Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. 

**We look forward to being of service to you.**

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk**
Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021)

Immunotherapy is also known as biologic therapy for cancer treatment. Immunotherapy is treatment which is carried out using certain parts of a person’s immune system to fight diseases such as cancer. Immunotherapy is can be done in two ways which includes either stimulating person’s own immune system to work harder or smarter to attack cancer cells or injecting immune system components, such as man-made immune system proteins to fight against cancer cells. Globally increasing instances of deaths due to cancer and growing population with cancer coupled with increasing awareness about cancer and various available treatments to cure cancer are major driving factors for the growth of cancer immunotherapy market.

This report identifies the cancer immunotherapy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cancer immunotherapy market.

Globally North America dominated the market for cancer immunotherapy in 2015 with accounting for nearly half of the global market due to high awareness and reported instances of cancer in the region. North America is expected to continue its domination during the period of study and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement in the field of medical science, increasing medical tourism, increased healthcare expenditure by many developing economies coupled with increasing awareness about cancer in the region.

This report on global cancer immunotherapy also covers different type of various cancer treated and market size in various geographical regions.

On the basis of cancer treated with cancer immunotherapy this report covers all the major cancer treated using cancer immunotherapy: Cancer monoclonal antibodies (Naked monoclonal antibodies and Conjugated monoclonal antibodies), Immune checkpoint inhibitors, Cancer vaccines, Non-specific immunotherapies and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cancer immunotherapy in each of the region.

This report identifies all the major companies operating in the global cancer immunotherapy market. Some of the major companies’ profiles in detail are as follows:

Bristol Mayer’s Squibb
F. Hoffmann-La Roche
Boehringer-Ingelheim
Pfizer Inc
Sanofi
Eli Lilly and Company

Additional Details

Publisher: Industry ARC
Reference: HCR 0197
Number of Pages: 0
Report Format: PDF
Publisher Information:

IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!

We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:
Table Of Contents for Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodie, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021) [Report Updated: 26-02-2016]

- 1. Cancer Immunotherapy – Market Overview
- 2. Executive Summary
- 3. Cancer Immunotherapy Market
  - Landscape
    - 3.1. Market Share Analysis
    - 3.2. Comparative Analysis
      - 3.2.1. Product Benchmarking
      - 3.2.2. End User Profiling
      - 3.2.3. Top 5 Financials Analysis
- 4. Cancer Immunotherapy – Market Forces
  - 4.1. Drivers
  - 4.2. Restraints
  - 4.3. Opportunities
  - 4.4. Challenges
  - 4.5. Porter’s Five Forces Analysis
    - 4.5.1. Bargaining Power of Suppliers
    - 4.5.2. Bargaining Power of Buyers
    - 4.5.3. Threat of New Entrants
    - 4.5.4. Threat of Substitutes
    - 4.5.5. Degree of Competition
- 5. Cancer Immunotherapy Market – Strategic Analysis
  - 5.1. Value Chain Analysis
  - 5.2. Pricing Analysis
  - 5.3. Opportunities Analysis
  - 5.4. Product/Market Life Cycle Analysis
  - 5.5. Suppliers and Distributors
- 6. Global Cancer Immunotherapy Market, By Cancer Type (2016-2021)
  - 6.1. Cancer monoclonal antibodies
    - 6.1.1. Naked monoclonal antibodies
    - 6.1.2. Conjugated monoclonal antibodies
  - 6.2. Immune checkpoint inhibitors
  - 6.3. Cancer vaccines
  - 6.4. Non-specific immunotherapies
  - 6.5. Others
  - 7.1. Europe
    - 7.1.1. Germany
    - 7.1.2. France
    - 7.1.3. Italy
    - 7.1.4. Spain
    - 7.1.5. Russia
    - 7.1.6. U.K.
    - 7.1.7. Rest of Europe
  - 7.2. Asia Pacific
    - 7.2.1. China
    - 7.2.2. India
    - 7.2.3. Japan
    - 7.2.4. South Korea
    - 7.2.5. Rest of Asia-Pacific
  - 7.3. North America
    - 7.3.1. U.S.
    - 7.3.2. Canada
    - 7.3.3. Mexico
  - 7.4. Rest of the World (RoW)
    - 7.4.1. Brazil
    - 7.4.2. Rest of RoW
  - 8.1. Expansion
  - 8.2. Technological Developments
  - 8.3. Merger & Acquisitions, and Joint Ventures
  - 8.4. Supply- Contract
- 9. Company Profiles (Top 10 Companies)
  - 9.1. Bristol Mayer’s Squibb
  - 9.2. F. Hoffmann-La Roche
  - 9.3. Boehringer-Ingelheim
  - 9.4. Pfizer Inc
  - 9.5. Sanofi
  - 9.6. Eli Lilly and Company
  - 9.7. Seattle Genetics
  - 9.8. Bayer Healthcare
  - 9.9. Intas Pharmaceuticals
  - 9.10. Novartis International AG
- 10. Appendix
  - 10.1. Abbreviations
  - 10.2. Sources
  - 10.3. Research Methodology
  - 10.4. Expert Insights

*More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"Financials would be provided on a best efforts basis for private companies" Appendix 10.1

Abbreviations 10.2 Sources 10.3 Research Methodology 10.4 Expert Insights
List Of Tables in Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021) [Report Updated: 26-02-2016]

No
How to Buy...

Cancer Immunotherapy Market: By Cancer Type (Cancer Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Non-Specific Immunotherapies & Others) & Geography-Forecast (2016-2021) [Report Updated: 26-02-2016]

Option 1 - Online
Go to our website and pay online with any major debit or credit card: https://www.bioportfolio.co.uk/product/80150

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ..........................................................................................................................
Job Title: ..............................................................................................................................
Your Email: ..........................................................................................................................
Your Contact Phone: ............................................................................................................
Company Name: ..................................................................................................................
Address: .............................................................................................................................
Post/Zip Code: ....................................................................................................................
Country: ............................................................................................................................
P. O. Number: .....................................................................................................................
Any Other Instructions: ........................................................................................................

Pricing Options: (please tick one)
☐ £36,525 | Single User Price
☐ £36,625 | Site License Price
☐ £36,845 | Enterprise License Price

Payment Options: (please tick one)
☐ Online Credit Card (we will email you the invoice with a payment link)
☐ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ........................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.